Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine: A single-center experience

Experimental and Clinical Endocrinology and Diabetes

Volumn 119, Issue 9, 2011, Pages 540-543

  Deutschbein, T ^a   Matuszczyk, A ^a   Moeller, L C ^a   Unger, N ^a   Yuece, A ^a   Lahner, H ^a   Mann, K ^a   Petersenn, S ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

adverse events; efficacy; follow up; outcome; progression; side effects; staging; toxicity; treatment

Indexed keywords

CALCITONIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DEXAMETHASONE; GRANISETRON; MESNA; VINCRISTINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CYSTITIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; FATIGUE; FEMALE; FOLLOW UP; HAIR LOSS; HUMAN; INFECTION; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PANCYTOPENIA; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SIDE EFFECT; SWEATING; THYROID MEDULLARY CARCINOMA; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CALCITONIN; CARCINOMA; COHORT STUDIES; CYCLOPHOSPHAMIDE; DACARBAZINE; FEMALE; GASTROINTESTINAL TRACT; HOSPITALS, UNIVERSITY; HUMANS; MALE; MIDDLE AGED; MYELOPOIESIS; NEOPLASM STAGING; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; THYROID NEOPLASMS; TUMOR BURDEN; VINCRISTINE;

EID: 80054747201     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0031-1279704     Document Type: Article

References (12)

1. Ball DW. Medullary thyroid cancer: monitoring and therapy. Endocrinol Metab Clin North Am 2007 36 823-837 (Pubitemid 47126253)
2. Kloos RT, Eng C, Evans DB et al,. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 2008 19 565-612
3. Roman S, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 2006 107 2134-2142 (Pubitemid 44665646)
4. Miccoli P, Minuto MN, Ugolini C et al,. Clinically unpredictable prognostic factors in the outcome of medullary thyroid cancer. Endocr Relat Cancer 2007 14 1099-1105 (Pubitemid 351252441)
5. Wu LT, Averbuch SD, Ball DW et al,. Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine. Cancer 1994 73 432-436 (Pubitemid 24030625)
6. Averbuch SD, Steakley CS, Young RC et al,. Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann Intern Med 1988 109 267-273
7. Therasse P, Arbuck SG, Eisenhauer EA et al,. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000 92 205-216
8. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958 53 457-481
9. Hartley A, Spooner D, Brunt AM. Management of malignant pheochromocytoma: a retrospective review of the use of MIBG and chemotherapy in the West Midlands. Clin Oncol (R Coll Radiol) 2001 13 361-366 (Pubitemid 33034920)
10. Edström Elder E, Hjelm Skog AL, Hoog A et al,. The management of benign and malignant pheochromocytoma and abdominal paraganglioma. Eur J Surg Oncol 2003 29 278-283 (Pubitemid 36395565)
11. Robinson BG, Paz-Ares L, Krebs A et al,. Vandetanib (100mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab 2010 95 2664-2671
12. Wells SA Jr, Gosnell JE, Gagel RF et al,. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 2010 28 767-772